Switching From Adalimumab to Infliximab

CompletedOBSERVATIONAL
Enrollment

21

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

February 17, 2014

Study Completion Date

February 17, 2014

Conditions
Crohn's Disease
Interventions
DRUG

Adalimumab and Infliximab

Patients with moderately to severely active Crohn's disease with primary non-response or loss of response to Adalimumab switch to Infliximab.

Trial Locations (16)

Unknown

Sint-Augustinus, Antwerp

UZ Antwerpen, Antwerp

Imelda Hospital, Bonheiden

Cliniques Universitaires Saint-Luc, Brussels

ULB université libre (erasme), Brussels

Ziekenhuis Oost-Limburg, Genk

University Hospital Ghent, Ghent

Virga Jesse hospital, Hasselt

AZ Groeninge, Kortrijk

UZ Leuven, Leuven

CHC (Centre Hospitalier Chrétien), Liège

CHU de liège, Liège

Hospital Maas en kempen, Maaseik

AZ Damiaan, Ostend

Clinique Saint-Pierre, Ottignies

Heilig Hartziekenhuis Roeselare, Roeselare

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Abbott

INDUSTRY

lead

University Hospital, Ghent

OTHER